Zivo Bioscience updates: USDA white paper, new poultry study, licensing talks with major animal health firm

Zivo Bioscience, Inc.

Submitted white paper to USDA for poultry coccidiosis product; expects jurisdiction confirmation within 8 weeks.
Began 21st in vivo study with AH Pharma to optimize product forms and reduce production costs.
Ongoing licensing discussions with a major animal health company; decision expected by end of Q2 2022.
Previous 20 studies validated efficacy and mechanism of action for the lead product candidate.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.